256 related articles for article (PubMed ID: 35671836)
1. Matrix metaloproteinases in vascular pathology.
Simões G; Pereira T; Caseiro A
Microvasc Res; 2022 Sep; 143():104398. PubMed ID: 35671836
[TBL] [Abstract][Full Text] [Related]
2. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.
Wang X; Khalil RA
Adv Pharmacol; 2018; 81():241-330. PubMed ID: 29310800
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
Siasos G; Tousoulis D; Kioufis S; Oikonomou E; Siasou Z; Limperi M; Papavassiliou AG; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1132-48. PubMed ID: 22519444
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and Biological Attributes of Matrix Metalloproteinases.
Cui N; Hu M; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
[TBL] [Abstract][Full Text] [Related]
5. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
Liu J; Khalil RA
Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
[TBL] [Abstract][Full Text] [Related]
6. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
Kim IS; Yang WS; Kim CH
Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.
Raffetto JD; Khalil RA
Biochem Pharmacol; 2008 Jan; 75(2):346-59. PubMed ID: 17678629
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling.
Chen Q; Jin M; Yang F; Zhu J; Xiao Q; Zhang L
Mediators Inflamm; 2013; 2013():928315. PubMed ID: 23840100
[TBL] [Abstract][Full Text] [Related]
10. Vascular extracellular matrix in atherosclerosis.
Chistiakov DA; Sobenin IA; Orekhov AN
Cardiol Rev; 2013; 21(6):270-88. PubMed ID: 23422022
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases and atherogenesis in dependence of age.
Kunz J
Gerontology; 2007; 53(2):63-73. PubMed ID: 17047333
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
13. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
Pauschinger M; Chandrasekharan K; Schultheiss HP
Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
[TBL] [Abstract][Full Text] [Related]
14. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.
Cabral-Pacheco GA; Garza-Veloz I; Castruita-De la Rosa C; Ramirez-Acuña JM; Perez-Romero BA; Guerrero-Rodriguez JF; Martinez-Avila N; Martinez-Fierro ML
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419373
[TBL] [Abstract][Full Text] [Related]
15. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC
Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693
[TBL] [Abstract][Full Text] [Related]
16. Regulation and involvement of matrix metalloproteinases in vascular diseases.
Amin M; Pushpakumar S; Muradashvili N; Kundu S; Tyagi SC; Sen U
Front Biosci (Landmark Ed); 2016 Jan; 21(1):89-118. PubMed ID: 26709763
[TBL] [Abstract][Full Text] [Related]
17. Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.
Chen Y; Peng W; Raffetto JD; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():267-299. PubMed ID: 28413031
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and their inhibitors in Fuchs endothelial corneal dystrophy.
Xu I; Thériault M; Brunette I; Rochette PJ; Proulx S
Exp Eye Res; 2021 Apr; 205():108500. PubMed ID: 33617849
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.
Benjamin MM; Khalil RA
Exp Suppl; 2012; 103():209-79. PubMed ID: 22642194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
